Lactobacillus casei prevents impaired barrier function in intestinal epithelial cells

被引:85
作者
Eun, Chang Soo [1 ]
Kim, Yong Seok [2 ]
Han, Dong Soo [1 ]
Choi, Joo Hyun [1 ]
Lee, A. Reum [1 ]
Park, Yoon Kyung [1 ]
机构
[1] Hanyang Univ, Guri Hosp, Dept Internal Med, Gyeonggi Do, South Korea
[2] Hanyang Univ, Guri Hosp, Dept Biochem, Gyeonggi Do, South Korea
关键词
Lactobacillus casei; epithelial barrier function; Caco-2; TIGHT JUNCTION; PARACELLULAR PERMEABILITY; PROBIOTIC THERAPY; CROHNS-DISEASE; T84; CELLS; INFLAMMATION; DYSFUNCTION; INFECTIONS; MODULATION; MECHANISM;
D O I
10.1111/j.1600-0463.2010.02691.x
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
071005 [微生物学]; 100108 [医学免疫学];
摘要
The exact effect of probiotics on epithelial barrier function is not well understood. The aims of this study were to evaluate cytokine-induced epithelial barrier dysfunction in intestinal epithelial cells (IECs) and to study the role of probiotics in the prevention of epithelial barrier dysfunction. Caco-2 cells grown on transwell chambers were stimulated with tumor necrosis factor (TNF)-alpha or interferon (IFN)-gamma basolaterally. Probiotic, Lactobacillus casei, was added 1 h before cytokine stimulation. MAPK inhibitors were added 15 min before L. casei stimulation. The electrical resistance and paracellular permeability of Caco-2 monolayers were measured. Distribution of zonula occludens (ZO)-1 protein was assessed by immunofluorescence, and Western blot analyses for ZO-1, p-Akt, and toll-like receptor (TLR) 2 were performed. Both TNF-alpha and IFN-gamma stimulation on Caco-2 cells decreased transepithelial resistance (TER), increased epithelial permeability, and decreased ZO-1 expression of Caco-2 cells. In contrast, pretreatment of L. casei reversed the cytokine-induced dysfunction of TER, epithelial permeability, and ZO-1 expression. Reversal of cytokine-induced dysfunction of TER and intestinal permeability by L. casei was abrogated with MAPK inhibitor treatment. Lactobacillus casei stimulation on Caco-2 cells increased TLR2 and p-Akt expression. Probiotic, L. casei, prevents cytokine-induced epithelial barrier dysfunctions in IECs.
引用
收藏
页码:49 / 56
页数:8
相关论文
共 28 条
[1]
TIGHT JUNCTIONS AND THE MOLECULAR-BASIS FOR REGULATION OF PARACELLULAR PERMEABILITY [J].
ANDERSON, JM ;
VANITALLIE, CM .
AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY, 1995, 269 (04) :G467-G475
[2]
The mechanism of action of probiotics [J].
Boirivant, Monica ;
Strober, Warren .
CURRENT OPINION IN GASTROENTEROLOGY, 2007, 23 (06) :679-692
[3]
Borruel N, 2003, AM J GASTROENTEROL, V98, P865, DOI 10.1111/j.1572-0241.2003.07384.x
[4]
Toll-like receptor 2 controls mucosal inflammation by regulating epithelial barrier function [J].
Cario, E. ;
Gerken, G. ;
Podolsky, D. K. .
GASTROENTEROLOGY, 2007, 132 (04) :1359-1374
[5]
Lactobacillus casei prevents the development of dextran sulphate sodium-induced colitis in Toll-like receptor 4 mutant mice [J].
Chung, Y. W. ;
Choi, J. H. ;
Oh, T. -Y. ;
Eun, C. S. ;
Han, D. S. .
CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 2008, 151 (01) :182-189
[6]
Cui HH, 2004, WORLD J GASTROENTERO, V10, P1521
[7]
Bacterial probiotic modulation of dendritic cells [J].
Drakes, M ;
Blanchard, T ;
Czinn, S .
INFECTION AND IMMUNITY, 2004, 72 (06) :3299-3309
[8]
The tight junction protein ZO-1 establishes a link between the transmembrane protein occludin and the actin cytoskeleton [J].
Fanning, AS ;
Jameson, BJ ;
Jesaitis, LA ;
Anderson, JM .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1998, 273 (45) :29745-29753
[9]
Prophylaxis of pouchitis onset with probiotic therapy: A double-blind, placebo-controlled trial [J].
Gionchetti, P ;
Rizzello, F ;
Helwig, U ;
Venturi, A ;
Lammers, KM ;
Brigidi, P ;
Vitali, B ;
Poggioli, G ;
Miglioli, M ;
Campieri, M .
GASTROENTEROLOGY, 2003, 124 (05) :1202-1209
[10]
Mucosal IL-10 and TGF-β play crucial roles in preventing LPS-driven, IFN-γ-mediated epithelial damage in human colon explants [J].
Jarry, Anne ;
Bossard, Celine ;
Bou-Hanna, Chantal ;
Masson, Damien ;
Espaze, Eric ;
Denis, Marc G. ;
Laboisse, Christian L. .
JOURNAL OF CLINICAL INVESTIGATION, 2008, 118 (03) :1132-1142